BUZZ-Australia's <a href="https://laohu8.com/S/NTI.AU">Neurotech International</a> jumps as US FDA grants rare disease status for drug candidate** Shares of Australia's Neurotech International NTI.AX rise as much as 52.6% to A$0.029, their biggest intraday pct gain since early-July 2020
** Stock at its highest level since April 23
** NTI stock up 10.5% currently
** Biopharmaceutical co says U.S. FDA granted rare pediatric disease designation for drug candidate, NTI164, for treatment of Rett syndrome
** Rett syndrome is a rare genetic neurological and developmental disorder that affects ways in which brain develops
** Nearly 15.3 million shares change hands, 13.2x the 30-day average volume
** Stock has fallen 61.8% this year, as 0024 GMT
(Reporting by Roshan Thomas in Bengaluru)
((Roshan.Thomas@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.